Compare · AIRS vs OPCH
AIRS vs OPCH
Side-by-side comparison of AirSculpt Technologies Inc. (AIRS) and Option Care Health Inc. (OPCH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AIRS and OPCH operate in Medical/Nursing Services (Health Care), so they compete in similar markets.
- OPCH is the larger of the two at $4.74B, about 76.3x AIRS ($62.1M).
- AIRS has been more active in the news (10 items in the past 4 weeks vs 6 for OPCH).
- OPCH has more recent analyst coverage (17 ratings vs 9 for AIRS).
- Company
- AirSculpt Technologies Inc.
- Option Care Health Inc.
- Price
- -
- -
- Market cap
- $62.1M
- $4.74B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Nursing Services
- Medical/Nursing Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 10
- 6
- Recent ratings
- 9
- 17
AirSculpt Technologies Inc.
AirSculpt Technologies, Inc. focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States. It offers custom body contouring using its AirSculpt procedure that removes unwanted fat in a minimally invasive procedure. The company provides fat removal procedures across treatment areas; and fat transfer procedures that use the patient's own fat cells to enhance the breasts, buttocks, hips, or other areas. Its body contouring procedures also include the Power BBL, a Brazilian butt lift procedure; the Up a Cup, a breast enhancement procedure; and the Hip Flip, an hourglass contouring procedure. As of October 5, 2021, it operated 16 centers across 13 states. The company was founded in 2012 and is headquartered in Miami Beach, Florida.
Option Care Health Inc.
Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides immunoglobulin infusion therapies for the treatment of immune deficiencies; anti-infective therapies and services; home infusion services to treat heart failures; and treatments for chronic inflammatory disorders, including Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders; and immunoglobulin infusion therapies. It also offers infusion therapies for bleeding disorders; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications. In addition, the company offers therapies that women need to survive and thrive through high-risk pregnancies; treatments to manage the progression of neurological disorders, such as amyotrophic lateral sclerosis and duchenne muscular dystrophy; and nursing services. The company is headquartered in Bannockburn, Illinois.
Latest AIRS
- Chief Executive Officer Jashnani Yogesh bought $24,047 worth of shares (31,000 units at $0.78), increasing direct ownership by 4% to 726,475 units (SEC Form 4)
- AirSculpt Technologies Announces First-Ever Nationwide Open House Event, "The Gift of Body Confidence"
- AirSculpt Technologies Announces Participation in the A.G.P. Virtual Consumer Showcase
- SEC Form 10-Q filed by AirSculpt Technologies Inc.
- AirSculpt Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Results of Operations and Financial Condition, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- AirSculpt Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- AirSculpt Technologies Reports Third Quarter Fiscal 2026 Results
- AirSculpt Technologies Announces Earnings Release Date, Conference Call, and Webcast for Third Quarter Fiscal 2026 Results
- Lake Street initiated coverage on AirSculpt Technologies with a new price target
- Amendment: SEC Form SCHEDULE 13G/A filed by AirSculpt Technologies Inc.
Latest OPCH
- Director Pate R Carter sold $205,472 worth of shares (6,492 units at $31.65), decreasing direct ownership by 31% to 14,128 units (SEC Form 4)
- SEC Form DEFM14A filed by Option Care Health Inc.
- SEC Form 10-Q filed by Option Care Health Inc.
- Option Care Health Announces Financial Results for the Third Quarter Ended September 30, 2026
- Option Care Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form PREM14A filed by Option Care Health Inc.
- SEC Form DEFA14A filed by Option Care Health Inc.
- SEC Form DEFA14A filed by Option Care Health Inc.
- SEC Form 8-K filed by Option Care Health Inc.
- CD&R and McKesson Corporation Sign Agreement to Acquire Option Care Health